Mutational profiling of 103 unresectable pancreatic ductal adenocarcinomas using EUS-guided fine-needle biopsy.

Autor: Buchberg J; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., de Stricker K; Department of Pathology, Odense University Hospital, Odense, Denmark., Pfeiffer P; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.; Department of Oncology, Odense University Hospital, Odense, Denmark.; Odense Pancreas Center (OPAC), Odense University Hospital, Odense, Denmark., Mortensen MB; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.; Odense Pancreas Center (OPAC), Odense University Hospital, Odense, Denmark.; Department of Surgery, Upper GI and HPB Section, Odense University Hospital, Odense, Denmark., Detlefsen S; Department of Pathology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.; Odense Pancreas Center (OPAC), Odense University Hospital, Odense, Denmark.

Publikováno v: Endoscopic ultrasound [Endosc Ultrasound] 2024 May-Jun; Vol. 13 (3), pp. 154-164. Date of Electronic Publication: 2024 Jul 03.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

Autor: Knudsen TA; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Stevenson K; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Werner L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Duke W; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Laurore C; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Gibson CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Nag A; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA., Thorner AR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA., Wollison B; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA., Hansen DL; Department of Hematology, Odense University Hospital, Odense, Denmark., Ellervik C; Department of Data and Innovation Support, Region Zealand, Soroe, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., El Fassi D; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark.; Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark., de Stricker K; Department of Pathology, Odense University Hospital, Odense, Denmark., Ocias LF; Statens Serum Institut, Copenhagen, Denmark., Brabrand M; Department of Hematology, Odense University Hospital, Odense, Denmark., Bjerrum OW; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark., Overgaard UM; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark., Frederiksen M; Department of Hematology, Hospital of Southern Jutland, Haderslev, Denmark., Kristensen TK; Department of Pathology, Odense University Hospital, Odense, Denmark., Kruse TA; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark., Thomassen M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark., Mourits-Andersen T; Department of Hematology, Hospital of South West Jutland, Esbjerg, Denmark., Severinsen MT; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Stentoft J; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Starklint J; Department of Hematology, Holstebro Hospital, Holstebro, Denmark; and., Neuberg DS; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Kjaer L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Larsen TS; Department of Hematology, Odense University Hospital, Odense, Denmark., Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Lindsley RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mullally A; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute, Cambridge, MA.

Publikováno v: Blood advances [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 2107-2119.

Prognostic value of O‐6‐methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.

Autor: Dahlrot, R. H., Dowsett, J., Fosmark, S., Malmström, A., Henriksson, R., Boldt, H., de Stricker, K., Sørensen, M. D., Poulsen, H. S., Lysiak, M., Söderkvist, P., Rosell, J., Hansen, S., Kristensen, B. W.

Publikováno v: Neuropathology & Applied Neurobiology; Feb2018, Vol. 44 Issue 2, p172-184, 13p

Evaluation and comparison of performances of six commercial NSP ELISA assays for foot and mouth disease virus in Thailand.

Autor: Seeyo, Kingkarn Boonsuya¹ (AUTHOR), Choonnasard, Amonrat¹ (AUTHOR), Chottikamporn, Jeeranant¹ (AUTHOR), Singkleebut, Sopha¹ (AUTHOR), Ngamsomsak, Parichart¹ (AUTHOR), Suanpat, Karnrawee² (AUTHOR), Balasubramanian, Nagendrakumar Singanallur³ (AUTHOR), Vosloo, Wilna³ (AUTHOR), Fukai, Katsuhiko⁴ (AUTHOR) fukai@affrc.go.jp

Publikováno v: Scientific Reports. 10/17/2024, Vol. 14 Issue 1, p1-8. 8p.

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT

Autor: Urbanska, E., Melchior, L., De Stricker, K., Sørensen, J.B., Santoni Rugiu, E.

Publikováno v: In Journal of Thoracic Oncology October 2018 13(10) Supplement:S946-S946